Abstract
Simple SummaryAs a preclinical model for personalized cancer therapy, the patient-derived xenograft (PDX) model is suitable because it provides the best representation of the original tumor, but it still has many limitations. We analyzed gynecologic cancer PDX models with their clinical information and gene expression profiling, and found that the success rate of PDX correlated with the patient’s tumor grade and prognosis. Moreover, we showed that the faster the tumor progressed in PDXs, the poorer the prognosis in ovarian cancer patients. We confirmed that the differentially expressed genes (DEGs) selected according to PDX engraftment status could be a prognosis marker of ovarian clear cell cancer patients. This study paves the way for a better application of the PDX in gynecologic cancer.Patient-derived xenografts (PDXs) are important in vivo models for the development of precision medicine. However, challenges exist regarding genetic alterations and relapse after primary treatment. Thus, PDX models are required as a new approach for preclinical and clinical studies. We established PDX models of gynecologic cancers and analyzed their clinical information. We subcutaneously transplanted 207 tumor tissues from patients with gynecologic cancer into nude mice from 2014 to 2019. The successful engraftment rate of ovarian, cervical, and uterine cancer was 47%, 64%, and 56%, respectively. The subsequent passages (P2 and P3) showed higher success and faster growth rates than the first passage (P1). Using gynecologic cancer PDX models, the tumor grade is a common clinical factor affecting PDX establishment. We found that the PDX success rate correlated with the patient’s prognosis, and also that ovarian cancer patients with a poor prognosis had a faster PDX growth rate (p < 0.0001). Next, the gene sets associated with inflammation and immune responses were shown in high-ranking successful PDX engraftment through gene set enrichment analysis and RNA sequencing. Up-regulated genes in successful engraftment were found to correlate with ovarian clear cell cancer patient outcomes via Gene Expression Omnibus dataset analysis.
Highlights
Gynecologic cancers are defined as cancers occurring in the human female reproductive system, composed of internal and external sex organs [1]
We confirmed that the established Patient-derived xenografts (PDXs) models maintained the histology of the original tumor via H&E staining (Supplementary Figure S1)
There was no association between patients’ survival and tumor tissue engraftment in cervical, vaginal, or uterine cancers (Figure 2B,C). These results suggest that the PDX success rate and tumor growth rate are associated with a poor prognosis in ovarian cancer
Summary
Gynecologic cancers are defined as cancers occurring in the human female reproductive system, composed of internal and external sex organs [1]. In Korea, the incidence rates for gynecologic cancers increased annually from 2005 until 2017. Gynecologic cancers frequently occur in postmenopausal women, with a high incidence rate in women aged 50–60 years [4,5]. In recent years, the incidence of gynecologic cancer has increased in women under the age of 39 and over the age of 80 [6]. Gynecologic cancer does occur in postmenopausal women; it can occur in women of all ages. The emergence of this cancer in a period of active living places an enormous burden on patients’ quality of life. Gynecologic cancer has become a major burden throughout women’s lives
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
